How Many Dechra Pharmaceuticals PLC (LON:DPH)’s Analysts Are Bearish?

Dechra Pharmaceuticals PLC (LON:DPH) Logo

Dechra Pharmaceuticals PLC (LON:DPH) Ratings Coverage

Among 2 analysts covering Dechra Pharmaceuticals PLC (LON:DPH), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Dechra Pharmaceuticals PLC had 3 analyst reports since July 10, 2018 according to SRatingsIntel. The rating was maintained by Numis Securities with “Add” on Tuesday, July 10. The rating was maintained by RBC Capital Markets with “Sector Performer” on Friday, November 23. On Monday, September 3 the stock rating was downgraded by Numis Securities to “Hold”. Below is a list of Dechra Pharmaceuticals PLC (LON:DPH) latest ratings and price target changes.

23/11/2018 Broker: RBC Capital Markets Rating: Sector Performer Old Target: GBX 2400.00 New Target: GBX 2100.00 Maintain
03/09/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 2950.00 Downgrade
10/07/2018 Broker: Numis Securities Rating: Add Old Target: GBX 2640.00 New Target: GBX 2950.00 Maintain

The stock decreased 0.64% or GBX 14 during the last trading session, reaching GBX 2160. About 237,112 shares traded. Dechra Pharmaceuticals PLC (LON:DPH) has 0.00% since December 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Dechra Pharmaceuticals plc develops, makes, sells, and markets veterinary pharmaceuticals and related products for veterinarians worldwide. The company has market cap of 2.21 billion GBP. The firm operates through the European Pharmaceuticals, the North American Pharmaceuticals, and the Pharmaceuticals Research and Development divisions. It has a 58.38 P/E ratio. It offers various endocrinology, dermatology and care, anesthesia and analgesia, cardiovascular disease, ophthalmology, and equine medicine products; food producing animal antimicrobials; poultry vaccines; and pet diets.

More important recent Dechra Pharmaceuticals PLC (LON:DPH) news were published by: Prnewswire.com which released: “Safeguard Scientifics Partner Company Putney To Be Acquired For $200M – PR Newswire” on December 31, 2017, also Globenewswire.com published article titled: “Kane Biotech – 2017 Year End and Fourth Quarter Financial Results and Business Update – GlobeNewswire”, Streetinsider.com published: “Form N-PX FIDELITY ADVISOR SERIES For: Jun 30 – StreetInsider.com” on August 23, 2018. More interesting news about Dechra Pharmaceuticals PLC (LON:DPH) was released by: Prnewswire.com and their article: “Safeguard Scientifics Announces First Quarter 2016 Financial Results – PR Newswire” with publication date: April 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.